Loading
A phase 2 trial of Rasburicase in Leukaemia, run by M.D. Anderson Cancer Center, completed.
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2 is a phase 2 interventional study registered as NCT01200485 by M.D. Anderson Cancer Center, with 55 participants recorded, started 2011-04 and reaching its primary completion in 2016-07. Interventions recorded: Rasburicase, Allopurinol. Conditions recorded: Leukemia, Lymphoma.
Linked to the drug Rasburicase because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
55 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2020-01-31), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Number of Participants (Incidence) of LTLS (Laboratory Tumor Lysis Syndrome)primary | Arm A (Rasburicase) | 21 | 1 participants | - | - | link |
| Arm B (Allopurinol) | 25 | 1 participants |
Shares Rasburicase, Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.